English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

REFERENCES Background: ASN100 is a combination of ASN-1 and ASN-2, two human monoclonal antibodies (mAbs) which selectively bind to 6 S. aureus cytotoxins. ASN100 is in development for prevention of S. aureus pneumonia in mechanically ventilated patients. A population pharmacokinetic (PK) model was developed for both ASN-1 and ASN-2 following monotherapy or simultaneous administration (ASN100) using dose-escalation data from a first-in-human study.

Population Pharmacokinetic Model for Intravenous ASN100 in Healthy Subjects